literature

HIV mutation literature information.

The prevalence of transmitted HIV drug resistance among MSM in Anhui province, China.

PMID: 25035709 2014 AIDS research and therapy

Result: A98G confers a low level of resistance to EFV and NVP, and while V179D in a URF strain confers a low level of resistance against EFV and an intermediate level of resistance against NVP, V179D in

Discussion: A98G and V179E were excluded from the WHO list of SDRMs because of high occurrence in viruses from treatment-naive individuals.

Discussion: A98G has been shown to confer low-level resistance against EFV and NVP, and V179D in CRF01_AE/CRF07_BC recombinant viruses has been shown to confer low-level resistance against EFV and intermediate level resistance against NVP, while V179D in CRF01_AE viruses does not affect resistance to any RT drugs (data not published).

Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia.

PMID: 25166019 2014 PloS one

Result: The Y181C/I (N = 5, 33.3%), A98S/G (n = 4, 27%), H221Y (n = 2, 13%) and P225H (N = 1, 7.5%) mutations were only seen in pre-treated patients.

A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.

PMID: 25259833 2014 AIDS (London, England)

Result: The next most common NNRTI-resistance mutations in subtype AFSU viruses were K103N (25 patients), Y181C (13 patients), G190A (8 patients), A98G (4 patients), V108I (3 patients), and Y188L (2 patients).

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.

PMID: 25397500 2014 Journal of the International AIDS Society

Table: A98G

HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya.

PMID: 25487529 2014 BMC research notes

Abstract: In addition, among patients failing second-line (20), six patients (30%) had NNRTI resistance; two patients on K103N and G190A mutations while V106A, Y184V, A98G, Y181C mutations per patient were also detected.

Result: However four patients had diverse drug mutations combinations of K103N and V108IV (n = 1); Y184V, G190A and T215Y (n = 1); K103N, M184V and T215Y (n = 1); and A98G, Y181

Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.

PMID: 23364785 2013 Journal of medical virology

Abstract: In the plasma virus from treatment experienced patients with Y181C, A98G, V108I, and/or K101E mutations in the pol gene, higher IC(50) values were found in line with reduced susceptibility data for ETR.

Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.

PMID: 23443042 2013 Journal of the International AIDS Society

Table: A98G

Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.

PMID: 23469241 2013 PloS one

Table: A98G

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

PMID: 23840622 2013 PloS one

Method: The following non-polymorphic ARV-selected mutations were classified as drug resistance mutations (DRM): (i) the NRTI resistance mutations M41L, A62V, K65RN, D67NG, T69D, T69 insertions, T69 deletion, K70REGQ, L74VI, V75MT, F77L, Y115F, F116Y, Q151M, M184VI, L210W, T215YFSDCIV, and K219QENR; (ii) the

HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana.

PMID: 23977189 2013 PloS one

Result: This case possessed HIV-1 RT mutations M41L, V90I, A98G, M184V and T215Y, and the major NFV-resistance mutation L90M in PR.

Table: A98G

Browser Board

Co-occurred Entities

Filtrator